Monday, March 17, 2025 | 02:36 AM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Strong product pipeline, valuations keep street positive on Aurobindo

The company delivered a muted show in the September quarter

pharmacy, drugs, medicine, pharma companies, pharmaceuticals
Premium

Ram Prasad Sahu Mumbai
The Aurobindo Pharma stock gained 3.5 per cent in trade on Wednesday despite a muted performance in the September quarter. Most analysts shrugged off the miss on operating performance and instead focused on the recovery in the US business in Q2 and the revenue visibility in that market.

Overall, the revenue was down 2 per cent, while the operating profit margin slipped 210 basis points over the year-ago quarter.

What pegged back the sales in the September quarter was the performance of the antiretroviral (ARV) segment, which reported a 71 per cent YoY decline in the revenue on a higher base. Higher

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in